Climb Bio reports positive SC formulation data; ITP data June 2026, pMN/SLE Q4 2026

Climb Bio, Inc.

Topline Phase 1 SC data: robust B-cell depletion similar to IV; generally safe and well-tolerated.
Fast Track Designation received for primary membranous nephropathy (pMN).
Initial ITP Phase 1b/2a data from low-dose cohort expected June 2026.
Initial pMN Phase 2 and SLE Phase 1b data expected Q4 2026.
Budoprutug is an anti-CD19 mAb targeting B-cell mediated diseases; trials enrolling to plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.